Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and
direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in …

Background No pooled analysis has been undertaken to assess the efficacy and safety of
the non‐vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin in the …

Atrial fibrillation (AF) is the most common sustained arrhythmia, causing a 2-fold increase in
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Recent versions of evidence-based guidelines on the management of atrial fibrillation (AF)
have been published by the European Society of Cardiology (ESC) in collaboration with the …

Objective To compare the risks of postendoscopy outcomes associated with warfarin with
direct oral anticoagulants (DOACs), taking into account heparin bridging and various types …

Objectives This cross-sectional survey explored the characteristics and outcomes of direct
oral anticoagulant (DOAC)–associated nontraumatic intracerebral hemorrhages (ICHs) by …

The human breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette
efflux transporter that uses ATP hydrolysis to expel xenobiotics from cells, including anti …

Particular concerns have been raised regarding the association between non‐vitamin K
antagonist oral anticoagulants (NOACs) and the risk of gastrointestinal bleeding (GIB); …

Background: Several bleeding risk scores have been validated in patients with atrial
fibrillation (AF). The ORBIT score has been recently proposed as a simple score with the …